Navigation Links
Pharmaceutical Executive Magazine's 2013 Drug "Brand of the Year" Awarded to Leading Merck Diabetes Drug Januvia
Date:3/26/2013

NEW YORK, March 26, 2013 /PRNewswire/ -- Pharmaceutical Executive, the monthly magazine and daily online publication of record on analytics, trends and personalities in the biopharmaceutical industry worldwide, announced today the choice for its 2013's drug Brand of the Year: Merck's Januvia [sitagliptin], a first in class dipeptide peptidase-4 inhibitor treatment for adult onset [Type II] diabetes.    

Brand of the Year is an independent, non-promotional designation, selected annually since 1998 by the publication's editorial staff and expert Advisory Board. It seeks to recognize FDA-authorized prescription medicines with a track record of clinical innovation as well as consistent, real-world performance and appeal to patients. It must also demonstrate novelty in the developer's approach to brand-building and market awareness activities.

Januvia was developed and has been marketed by Merck since 2006, and, along with its sister drug Janumet, is now the biggest-selling therapeutic franchise in the company's 122 year history.  "We are pleased to devote our March cover to this important medicine, not only because of its breakthrough status in regulating blood sugar among Type II patients, with fewer side effects, but also for the higher profile it has given to a debilitating chronic condition that contributed to the deaths of more than 4.6 million people worldwide in 2011," said Pharm Exec Editor-in-Chief William Looney .

The story, authored by Senior Editor Ben Comer , features interviews and backgrounders with several top Merck executives, representatives of the original product launch team, patient groups and independent medical experts, all of whom point to the need for further progress by the pharmaceutical industry in combating persistent challenges in managing this growing illness – despite the success of clinically effective medicines like Januvia, half of all diabetes patients still fail to complete the drug therapy recommended by their physician.  

Full text of the story as well as a video display summary is available on the Pharmaceutical Executive web site, at www.pharmexec.com.  Editorial staff are also available for comment and interviews:  please contact Email.

Pharmaceutical Executive probes the interface of business practice and public policy for the global biopharmaceutical, vaccine and medical device industries.  PharmExec's editorial remit covers strategy in the "c-suite" as well as regulatory and legal actions; sales promotion and marketing; R&D; finance; human resources; pricing and market access; and new technology.  Published by Advanstar Communications, PharmExec's editorial content is available in the award-winning monthly print edition as well as in a number of digital platforms.  

Media Contact: 
William Looney 
212-951-6735

This press release was issued through eReleases® Press Release Distribution. For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Pharmaceutical Executive
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
2. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
3. Pharmaceutical Industry Service Company Awarded The UKs Most Prestigious Business Accolade in Recognition of Outstanding Achievement in International Trade
4. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
5. Simcere Pharmaceutical Group to Announce First Quarter 2012 Financial Results on Wednesday, May 9, 2012
6. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
7. Thomson Reuters Launches New Mobile Oncology Decision Support Solution for R&D Pharmaceutical Leaders
8. Amgen to Acquire Mustafa Nevzat, a Leading Privately Held Turkish Pharmaceutical Company
9. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
10. Icahn Issues Statement Regarding Amylin Pharmaceuticals
11. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/4/2017)... Mass. , Oct. 4, 2017 ... of single-use, self-contained, illuminating medical devices, today announced ... National Health Surveillance Agency (or Agência Nacional de ... The first single-use, cordless surgical retractor with integrated ... provides optimal access, illumination and exposure of a ...
(Date:10/2/2017)... , Oct. 2, 2017 Halo Labs announces the ... analysis system called the HORIZON at MIBio 2017 in ... subvisible and visible particulate matter in biopharmaceutical samples with unprecedented speed ... of the novel technique Backgrounded Membrane Imaging. ... The HORIZON subvisible particle analysis system ...
(Date:9/27/2017)... -- Commended for their devotion to personalized service, SMP Pharmacy Solutions ... in the South Florida Business Journal,s 50 Fastest-Growing Companies, and ... the national specialty pharmacy has found its niche.  To that ... be honored by SFBJ as the 2017 Power Leader in ... receive his award in October, Bardisa said of the three ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer ... one of the most popular and least understood books in the Holy Scriptures, Revelation. ... descriptions that have baffled scholars for centuries. Many have tossed it off as mere ...
(Date:10/13/2017)... ... 2017 , ... “The Journey: From the Mountains to the Mission Field”: the ... in the Philippines. “The Journey: From the Mountains to the Mission Field” is the ... She has taught all ages and currently teaches a class of ladies at her ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are ... cessation in breathing. Oral appliances can offer significant relief to about 75 percent ...
(Date:10/12/2017)... ... ... IsoComforter, Inc. ( https://isocomforter.com ), one of the Nation’s premier ... of the shoulder pad. The shoulder pad provides optimal support and full contact ... using cold therapy. By utilizing ice and water that is circulated from an insulated ...
(Date:10/12/2017)... ... 12, 2017 , ... Information about the technology: , Otomagnetics ... enable prevention of a major side effect of chemotherapy in children. Cisplatin and ... For cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. ...
Breaking Medicine News(10 mins):